In a recent interview with Drug Discovery News, Brian Wilson, Director of Sales & Business Development at Aptar Active Material Science, shared his perspective on the challenges and opportunities surrounding nitrosamine mitigation in the pharmaceutical industry.

The conversation explores why nitrosamine mitigation continues to be a key industry focus, the complexities associated with remediation efforts, and the importance of identifying effective risk management strategies throughout the product lifecycle.

The interview also highlights emerging approaches to nitrosamine mitigation, including the growing interest in packaging-based solutions that can complement broader pharmaceutical development and quality strategies. As regulatory expectations continue to evolve, this discussion helps advance industry understanding and encourages collaboration around practical mitigation approaches.

Read the full interview in Drug Discovery News to learn more about the current nitrosamine landscape and Aptar Active Material Science’s perspective on addressing this ongoing challenge.